Trial Profile
A Randomized, DB, PC and AC, Parallel Group, Dose-Response Study to Evaluate the Efficacy and Safety of 3 Fixed Dosages of Extended Release OROS Paliperidone (6, 9, 12 mg/Day) and Olanzapine (10 mg/Day), With Open-Label Extension, in the Treatment of Subjects With Schizophrenia - Open Label Phase
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 04 Aug 2016
Price :
$35
*
At a glance
- Drugs Paliperidone (Primary)
- Indications Schizophrenia
- Focus Adverse reactions
- Sponsors Janssen Research & Development
- 22 Apr 2008 New trial record.